Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | ABCB1 | P08183 | 12/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5046552 | 1.00 | LMNA (0.42) | LMNAALDH1A1TDP1ABCB1TSHR | |
| SCHEMBL723158 | 1.00 | LMNA (0.42) | LMNAALDH1A1TDP1ABCB1TSHR | |
| SCHEMBL6158095 | 0.83 | LMNA (0.42) | LMNAALDH1A1TDP1TSHRTHRB | |
| Hydrochloric Acid SCHEMBL11700049 | 0.81 | LMNA (0.40) | LMNAALDH1A1TDP1TSHRTHRB | |
| SCHEMBL1608533 | 0.79 | THRB (0.43) | TDP1ABCB1THRB | |
| SCHEMBL20753133 | 0.78 | LMNA (0.42) | LMNAALDH1A1TDP1TSHRTHRB | |
| SCHEMBL22215204 | 0.78 | TSHR (0.40) | ABCB1TSHRMEN1KMT2A | |
| SCHEMBL11142181 | 0.77 | ALDH1A1 (0.32) | LMNAALDH1A1TDP1 | |
| SCHEMBL5046571 | 0.76 | ABCB1 (0.38) | ABCB1MEN1KMT2A | |
| SCHEMBL4158985 | 0.76 | LMNA (0.40) | LMNAALDH1A1TDP1TSHRTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8492560-B2 | Quinazoline derivatives as angiogenesis inhibitors | ASTRAZENECA AB (SE) | 2013-07-23 | — | — | US | disclosed |
| US-20120197027-A1 | Quinazoline Derivatives as Angiogenesis Inhibitors | STOKES ELAINE S E (GB) | 2012-08-02 | — | — | US | disclosed |
| US-7371765-B2 | Quinoline derivatives having VEGF inhibiting activity | ASTRAZENECA AB (SE) | 2008-05-13 | — | — | US | disclosed |
| US-7074800-B1 | Quinazoline derivatives as angiogenesis inhibitors | ASTRAZENECA AB (SE) | 2006-07-11 | — | — | US | disclosed |
| US-20060004017-A1 | Quinazoline derivatives as angiogenesis inhibitors | ASTRAZENECA AB | 2006-01-05 | — | — | US | disclosed |
| US-6887874-B2 | Cinnoline compounds | ASTRAZENECA AB (SE) | 2005-05-03 | — | — | US | disclosed |
| US-20030212055-A1 | Cinnoline compounds | ASTRAZENECA AB (SE) | 2003-11-13 | — | — | US | disclosed |
| US-20030207878-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2003-11-06 | — | — | US | disclosed |
| EP-1313726-A1 | QUINOLINE DERIVATIVES HAVING VEGF INHIBITING ACTIVITY | AstraZeneca AB (SE) | 2003-05-28 | — | — | EP | disclosed |
| EP-1311500-A2 | INDOLE, AZAINDOLE AND INDAZOLE DERIVATIVES HAVING VEGF INHIBITING ACTIVITY | AstraZeneca AB (SE) | 2003-05-21 | — | — | EP | disclosed |
| EP-1309587-A1 | CINNOLINE COMPOUNDS | AstraZeneca AB (SE) | 2003-05-14 | — | — | EP | disclosed |
| WO-2002016348-A1 | ANTIANGIOGENIC BICYCLIC DERIVATIVES | ASTRAZENECA AB (SE) | 2002-02-28 | — | — | WO | disclosed |
| WO-2002012226-A1 | QUINOLINE DERIVATIVES HAVING VEGF INHIBITING ACTIVITY | ASTRAZENECA AB (SE) | 2002-02-14 | — | — | WO | disclosed |
| WO-2002012228-A1 | CINNOLINE COMPOUNDS | ASTRAZENECA AB (SE) | 2002-02-14 | — | — | WO | disclosed |
| WO-2002012227-A2 | INDOLE, AZAINDOLE AND INDAZOLE DERIVATIVES HAVING VEGF INHIBITING ACTIVITY | ASTRAZENECA AB (SE) | 2002-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120197027-A1 | Quinazoline Derivatives as Angiogenesis Inhibitors | VEGFA, FLT1, KDR | LMNA 4202/4885ALDH1A1 822/4885TDP1 3001/4885 |
| US-20030207878-A1 | Chemical compounds | CYP3A7, HTR3C, CNR1 | LMNA 1195/4885ALDH1A1 1354/4885TDP1 2732/4885 |
| US-20030212055-A1 | Cinnoline compounds | VEGFA, PGF, CCR7 | LMNA 1971/4885ALDH1A1 335/4885TDP1 3113/4885 |
| US-20060004017-A1 | Quinazoline derivatives as angiogenesis inhibitors | FLT4, NOS3, FLT1 | LMNA 3352/4885ALDH1A1 3323/4885TDP1 4766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.